The Journal of Prevention of Alzheimer s Disease · 2022 · 123 citations · 39 references
MedicineClinical SciencesHematologyClinical BiochemistryClinical Research RegulationTransfusion MedicineBiomarker AnalysisBiomarker DevelopmentBiomarker DiscoveryBiomarker ValidationClinical HematologyClinical TrialsBiomarker Clinical UtilityBiomarker Data CollectionBlood Biomarker MonitoringBlood-based BiomarkersClinical Biomarker AssaysClinical Biomarker ImplementationClinical Biomarker TranslationNovel Circulating Biomarkers
Timely and accurate diagnosis of Alzheimer's disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers have the potential to be accurate, cost-effective, and easily accessible for widespread clinical use, and could facilitate timely diagnosis. The EU/US CTAD Task Force met in May 2022 in a virtual meeting to discuss pathways to implementation of blood-based markers in clinical practice. Specifically, the CTAD Task Force assessed: the state-of-art for blood-based markers, the current use of blood-based markers in clinical trials, the potential use of blood-based markers in clinical practice, the current challenges with blood-based markers, and the next steps needed for broader adoption in clinical practice.
39
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura, Naoki Kaneko, Victor L. Villemagne et al. · Nature · 2018 · 1.7K citations · Full text
Thomas G. Beach, Sarah E. Monsell, Leslie E. Phillips et al. · Journal of Neuropathology & Experimental Neurology · 2012 · 1.1K citations · Full text
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Suzanne E. Schindler, James G. Bollinger, Vitaliy Ovod et al. · Neurology · 2019 · 903 citations · Full text